# Gynecologic Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Eva Perón (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML025-SYN
- Date: 2026-02-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Henrietta Osei-Bonsu, MD
- Calendar frame: modern shifted

- Requested by: Lucía Barragán, MD

## Reason for consultation

A friable, exophytic cervical mass about 4 cm across in a 31-year-old woman who has never had cervical screening, with four months of bleeding after intercourse and between periods and iron deficiency anemia. A punch biopsy, HPV test and cytology were taken today. Please see her on the day the biopsy result is given, to confirm the diagnosis, stage the disease, advise on treatment by stage, and counsel her about fertility and ovarian function, and help us give her the result as she has asked. **S**

## History

Ms. Perón, a 31-year-old foundation director, is seen at the request of Dr. Barragán on the day she was told her biopsy result. The consultation is in Spanish through a professional medical interpreter, at her wish. She has had four months of bleeding after intercourse and between periods, with heavier periods, tiredness and a pelvic ache. She has never had cervical screening and was not vaccinated against HPV. She has no children and has not been pregnant. Dr. Barragán gave her the diagnosis in Spanish earlier in this visit; she has heard it, asked whether it can be cured, whether she can keep working, and whether she could have children, and asked that I explain the next steps to her directly. **S**

## Examination

| System | Finding |
|---|---|
| General | Pale; pulse 90, blood pressure 112/70 |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Pelvic | With her consent and a chaperone: a friable exophytic tumor about 4.5 cm across replacing the cervix; colposcopy of the vagina shows no spread to the vaginal walls; on rectovaginal examination the left parametrium is thickened and nodular but does not reach the pelvic wall; the right parametrium and the rectal mucosa are free |

BP 112/70 mmHg; pulse 90 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 52.8 kg; BMI 19.4 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Barragán's intake note. Cervical punch biopsy: invasive squamous cell carcinoma. HPV test positive for HPV 16; cytology with squamous cancer cells. Hemoglobin 9.4 g/dL, ferritin 6 ng/mL. Creatinine 0.7 mg/dL, eGFR 117 today. PHQ-9 9 and GAD-7 9 today. Creatinine: 0.7 mg/dL; eGFR: 117 mL/min/1.73 m²; Pelvic pain, worst in the past week (0 to 10): 4; PHQ-9: 9; GAD-7: 9. All results are synthetic.

## Assessment

1. **Squamous cell carcinoma of the cervix** (C53.9). Invasive squamous cell carcinoma of the cervix related to HPV 16, about 4.5 cm with clinical spread into the left parametrium: at least FIGO 2018 stage IIB on examination. FIGO 2018 allows imaging to assign stage: a pelvic MRI defines local extent and an FDG PET-CT looks for nodal and distant spread, which would change the radiation fields and the stage. With parametrial spread, radical hysterectomy is not advised; the standard treatment, with intent to cure, is pelvic external beam radiation with weekly cisplatin, followed by image-guided brachytherapy, completed within eight weeks, because a longer overall time lowers the chance of cure. Kidney function allows cisplatin. HIV testing is recommended at diagnosis. Chemoradiation will end her ability to carry a pregnancy and will very likely end ovarian function; egg or embryo freezing needs about two weeks of stimulation and would delay treatment slightly, and laparoscopic ovarian transposition can sometimes preserve hormone function; any later pregnancy would need a gestational carrier. The decision is hers. Bleeding is now light; if it becomes heavy, vaginal packing or a few early radiation fractions control it. Anemia should be corrected before radiation with iron, and hemoglobin watched weekly during it. Acetaminophen is the right analgesic; anti-inflammatory painkillers should be avoided with cisplatin. The diagnosis was given to her first, in her language, and she asked to hear everything; I explained the plan to her directly and answered each of her questions honestly. **S**
2. **Iron deficiency anemia** (D50.0). From chronic tumor bleeding; oral iron is reasonable now that the bleeding is lighter, with transfusion only if hemoglobin falls sharply or she has symptoms. **S**

## Recommendations

1. Pelvic MRI and FDG PET-CT within ten days to assign the FIGO 2018 stage.
2. HIV and hepatitis C tests now.
3. If staging confirms stage IIB without nodal or distant spread: pelvic external beam radiation 45 Gy in 25 fractions with cisplatin 40 mg/m2 weekly, then image-guided high-dose-rate brachytherapy, all within eight weeks.
4. Before treatment, her decision about egg or embryo freezing (reproductive endocrinology within days if she wants it) or ovarian transposition; treatment should not be delayed beyond about two weeks.
5. Continue ferrous sulfate and acetaminophen; no anti-inflammatory painkillers during cisplatin; weekly blood count, creatinine and magnesium during treatment.
6. Oncology social worker from today; PHQ-9 and GAD-7 at diagnosis, before treatment, mid-treatment and after.
7. All discussions with her directly, in Spanish with a professional interpreter when the clinician does not speak Spanish; information shared only with the people she chooses.
8. After treatment: PET-CT at about three months, a vaginal dilator, and hormone therapy if ovarian failure occurs.

## Strengths and supports

- Supports: a close friend and a long-time colleague at the foundation; her work gives her purpose. She would like the hospital's spiritual care team offered when she is in treatment **S**

## Communication

Discussed with Dr. Barragán, who was present. The diagnosis, the staging plan and the likely treatment were explained to Ms. Perón in Spanish through the interpreter, and she was given written information in Spanish. She chose to tell her family herself; no one else has been given information. She decides who receives this note. **S**

## Follow-up

Gynecologic oncology review with the staging results in about two weeks, jointly with Dr. Barragán, to confirm the stage and her treatment and fertility decisions. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027), National Comprehensive Cancer Network
- Revised FIGO staging for carcinoma of the cervix uteri (2018 (published 2019)), International Federation of Gynecology and Obstetrics (International Journal of Gynecology and Obstetrics)
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update (2018), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023), American Society of Clinical Oncology (Journal of Clinical Oncology)
